RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1260 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating for Regeneron Pharmaceuticals, maintaining a price target of $1260.
October 25, 2024 | 5:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Regeneron Pharmaceuticals, maintaining a price target of $1260, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and a high price target by RBC Capital suggests positive sentiment and confidence in Regeneron's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100